Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2: CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional Study

被引：0

作者：

Ballard, Morgan ^{[1
]}

Toukatly, Mirna ^{[2
]}

Bean, Gregory ^{[3
]}

Jalikis, Florencia ^{[4
]}

Krings, Gregor ^{[3
]}

Schmidt, Rodney ^{[4
]}

Chen, Yunn-Yi ^{[3
]}

Dintzis, Suzanne

Troxell, Megan ^{[5
]}

West, Robert ^{[6
]}

Sibley, Richard ^{[5
]}

Allison, Kimberly ^{[6
]}

机构：

[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[2] Univ Washington, Med Ctr, Seattle, WA 98195 USA

[3] UCSF, San Francisco, CA USA

[4] Univ Washington, Seattle, WA 98195 USA

[5] Stanford Univ, Med Ctr, Stanford, CA 94305 USA

[6] Stanford Univ, Stanford, CA 94305 USA

来源：

MODERN PATHOLOGY | 2018年 / 31卷

关键词：

D O I：

暂无

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

139

引用

页码：47 / 48

页数：2

共 50 条

[1] Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2:CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional Study
Ballard, Morgan
Toukatly, Mirna
Bean, Gregory
Jalikis, Florencia
Krings, Gregor
Schmidt, Rodney
Chen, Yunn-Yi
Dintzis, Suzanne
Troxell, Megan
West, Robert
Sibley, Richard
Allison, Kimberly
LABORATORY INVESTIGATION, 2018, 98 : 47 - 48
[2] Pathologic Features and Clinical Outcomes of Breast Cancers with HER2/CEP17 ratio <2.0 and mean HER2 signals /cell >6.0 by FISH; A Multi-Institutional Study
Ballard, Morgan
Toukatly, Mirna
Bean, Gregory
Jalikis, Florencia
Krings, Gregor
Schmidt, Rodney
Chen, Yunn-Yi
Rendi, Mara
Dintzis, Suzanne
Troxell, Megan
West, Robert
Sibley, Richard
Allison, Kimberly
LABORATORY INVESTIGATION, 2018, 98 : 48 - 48
[3] Pathologic Features and Clinical Outcomes of Breast Cancers with HER2/CEP17 ratio <2.0 and mean HER2 signals/cell >6.0 by FISH; A Multi-Institutional Study
Ballard, Morgan
Toukatly, Mirna
Bean, Gregory
Jalikis, Florencia
Krings, Gregor
Schmidt, Rodney
Chen, Yunn-Yi
Rendi, Mara
Dintzis, Suzanne
Troxell, Megan
West, Robert
Sibley, Richard
Allison, Kimberly
MODERN PATHOLOGY, 2018, 31 : 48 - 48
[4] Breast Cancers with < 4 HER2 Signals/cell and Amplified HER2:CEP17 Ratios by FISH: Pathologic Features and Clinical Outcomes of Cases with "CEP17 Monosomy"
Ballard, Morgan
Troxell, Megan
Jensen, Kristin
Allison, Kimberly H.
LABORATORY INVESTIGATION, 2017, 97 : 31A - 31A
[5] Breast Cancers with < 4 HER2 Signals/cell and Amplified HER2:CEP17 Ratios by FISH: Pathologic Features and Clinical Outcomes of Cases with "CEP17 Monosomy"
Ballard, Morgan
Troxell, Megan
Jensen, Kristin
Allison, Kimberly H.
MODERN PATHOLOGY, 2017, 30 : 31A - 31A
[6] HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemotherapy
Livasy, Chad A.
Limentani, Kimberly
Calhoun, Benjamin C.
Limentani, Steven
CANCER RESEARCH, 2015, 75
[7] Clinicopathologic Features of Breast Cancers with HER2/CEP17 Ratio <2, HER2 Copy Number ≥4 and <6 Signals/Cell
Xu, Jin
Brogi, Edi
Ventura, Katia
Ross, Dara
Dang, Chau
Robson, Mark
Norton, Larry
Morrow, Monica
Wen, Hannah
MODERN PATHOLOGY, 2019, 32
[8] Clinicopathologic Features of Breast Cancers with HER2/CEP17 Ratio <2, HER2 Copy Number ≥4 and <6 Signals/Cell
Xu, Jin
Brogi, Edi
Ventura, Katia
Ross, Dara
Dang, Chau
Robson, Mark
Norton, Larry
Morrow, Monica
Wen, Hannah
LABORATORY INVESTIGATION, 2019, 99
[9] HER2 Testing by FISH: Discordance between HER2 Signals Per Cell and HER2:CEP 17 Ratio
Dintzis, S. M.
Allison, K. H.
Schmidt, R. A.
CANCER RESEARCH, 2010, 70
[10] Prevalence of polysomy 17 by OncoScan in Fluorescence In Situ Hybridization (FISH) HER2 Gene amplification by HER2 gene copy number of > 6.0 with HER2/CEP17 ratio of < 2.0 in breast cancer
Apple, Sophia
Murata-Collins, Joyce
LABORATORY INVESTIGATION, 2018, 98 : 45 - 45

← 1 2 3 4 5 →

Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2: CEP17 ratio &gt; 2.0 but &lt; 4 HER2 signals/cell; A Multi-Institutional Study

Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2: CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional Study